.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,879,364

« Back to Dashboard

Details for Patent: 7,879,364

Title:Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Inventor(s): Warrell, Jr.; Raymond P. (Westfield, NJ), Pandolfi; Pier Paolo (New York, NY), Gabrilove; Janice L. (New York, NY)
Assignee: Memorial Sloan-Kettering Cancer Center (New York, NY)
Filing Date:Sep 30, 2005
Application Number:11/239,704
Claims:1. A method of treating a solid tumor comprising administering to a human patient having a solid tumor a therapeutically effective amount of arsenic trioxide, wherein the solid tumor is a cancer of the digestive tract, esophagus, liver, stomach, colon, brain, bone, breast, or lung or is a sarcoma.

2. The method of claim 1, wherein the solid tumor is a sarcoma.

3. The method of claim 2, wherein the sarcoma is prostate cancer.

4. The method of claim 1 wherein the amount of arsenic trioxide administered is about 1 mg to about 40 mg per day.

5. The method of claim 1, wherein the therapeutically effective amount of arsenic trioxide is based on the weight of the patient.

6. The method of claim 5, wherein the therapeutically effective amount of arsenic trioxide is about 0.1 to about 5.0 mg/kg body weight of the patient.

7. The method of claim 6, wherein the therapeutically effective amount of arsenic trioxide is administered to the patient daily for five days.

8. The method of claim 7, wherein the daily administration of arsenic trioxide for five days is repeated once per month until tumor growth is inhibited or until the tumor shows signs of regression.

9. The method of claim 5, wherein the therapeutically effective amount of arsenic trioxide is about 0.15 mg of arsenic trioxide per kg of body weight of the patient per day.

10. The method claim 1 wherein the solid tumor is a cancer of the digestive tract.

11. The method of claim 1 wherein the solid tumor is a cancer of the esophagus.

12. The method of claim 1 wherein the solid tumor is a cancer of the liver.

13. The method of claim 1 wherein the solid tumor is a cancer of the stomach.

14. The method of claim 1 wherein the solid tumor is a cancer of the colon.

15. The method of claim 1 wherein the solid tumor is a cancer of the brain.

16. The method of claim 1 wherein the solid tumor is a cancer of the bone.

17. The method of claim 1 wherein the solid tumor is a cancer of the breast.

18. The method of claim 1 wherein the solid tumor is a cancer of the lung.

19. The method of claim 1, comprising administering the therapeutically effective amount of arsenic trioxide to the patient in combination with a chemotherapeutic agent.

20. The method of claim 1, comprising administering the therapeutically effective amount of arsenic trioxide to the patient in combination with radiation treatment.

21. The method of claim 1, wherein the solid tumor is refractory to other therapy.

22. The method of claim 1, wherein the arsenic trioxide is administered intravenously.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc